Register for free
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

763.00 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Eli Lilly Launches AI, Machine Learning Platform Called TuneLab For Biotech Companies
The platform will provide biotech companies access to drug discovery models trained on years of Lilly's research data, the company stated. 
Via Stocktwits
Topics Artificial Intelligence
2 Growth Stocks with Explosive Upside and 1 We Brush Off
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
Topics Credit Cards
1 Reason Every Investor Should Know About Novo Nordisk (NVO)
The company could be on the verge of turning the tide in the battle over weight loss drugs. 
Via The Motley Fool
Eli Lilly's Jaypirca Surpasses Chemoimmunotherapy For Untreated Blood Cancer Patients
Jaypirca outperformed chemoimmunotherapy in progression-free survival for chronic lymphocytic leukemia patients in a Phase 3 trial, with positive trends in overall survival. 
Via Benzinga
Chinese Drugmakers Flooded US With Wegovy Copy Ingredients — Now They Are Pivoting To Generics: Report
Via Stocktwits
2024 R&D Spending and Intensity Benchmarks
Via PRLog
Topics Supply Chain
Ozempic Is The New Botox And Big Pharma Is Printing Billions
Ozempic and Zepbound have helped Novo Nordisk and Eli Lilly achieve a combined market cap topping $900 billion. 
Via Benzinga
Looking At Eli Lilly's Recent Unusual Options Activity
 
Via Benzinga
Unpacking Q2 Earnings: Eli Lilly (NYSE:LLY) In The Context Of Other Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Eli Lilly (NYSE:LLY) and the best and worst... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
FDA Tightens Grip On Safe Weight Loss Drugs, WHO Adds Them To Essential Medicines List
FDA introduces a green list to block unsafe GLP-1 drug imports, while WHO updates its essential medicines list to include diabetes and cancer treatments. 
Via Benzinga
Think It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time.
The market may have been too quick to dismiss this biotech's pipeline prospects after a recent trial result. 
Via The Motley Fool
The Best Growth ETF to Invest $2,000 in Right Now
This ETF has shown long-term market-beating ability. 
Via The Motley Fool
Topics ETFs
3 Stocks to Buy and Hold Forever
These stocks are built for the long run. 
Via The Motley Fool
Topics Intellectual Property
Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data
Skye Bioscience's latest data show nimacimab boosted tirzepatide's weight loss effects and reduced obesity treatment rebound risk. 
Via Benzinga
Is Eli Lilly Stock a Buy After Gaining 5% in 1 Day?
The company's innovative engine continues to function well. 
Via The Motley Fool
Topics World Trade
2 S&P 500 Dividend Stocks That Could Climb More Than 20% According to Wall Street Analysts
Consensus price targets set by experts who follow these businesses are way above their recent prices. 
Via The Motley Fool
Topics Stocks
Down 34%, Should You Buy the Dip on Viking Therapeutics?
Viking aims to enter the billion-dollar weight loss drug market. 
Via The Motley Fool
FDA Breakthrough Status Awarded To Lilly-Merck Combo Drug For Advanced Non-Small Cell Lung Cancer
Eli Lilly's olomorasib with Merck's Keytruda receives FDA Breakthrough Therapy status for KRAS G12c lung cancer, supported by trial results. 
Via Benzinga
ETF Traders Are Quietly Positioning For Market Turbulence: Direxion
Direxion MD Edward Egilinsky says traders are locking profits, hedging market highs, and using Palantir inverse ETFs for tactical moves. 
Via Benzinga
Topics ETFs
Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years
Both companies have made significant progress in recent years. 
Via The Motley Fool
The 6 Best Stocks to Buy Right Now in September (2025)!
There is something for everyone in this list of excellent stocks to buy. 
Via The Motley Fool
Where Will Eli Lilly Be in 3 Years?
The weight-loss drug opportunity could approach $100 billion by the end of the decade. 
Via The Motley Fool
Topics Intellectual Property
The Problem With Weight Loss Stocks
There are new ways to tackle weight loss, but the stocks leading the way are lagging. 
Via The Motley Fool
Topics Economy
After Copycat Boom, China's Drugmakers Target Global Generics
Chinese suppliers of semaglutide and tirzepatide that fueled a U.S. weight-loss drug boom are pivoting to generics as FDA crackdowns. 
Via Benzinga
Topics Supply Chain
This House of Representative Just Bought Up To $245K In Eli Lilly Stock
 
Via Benzinga
Defiance Launches LLYZ: The First 2X Short ETF for Eli Lilly
From Defiance ETFs
Via GlobeNewswire
Is Novo Nordisk Stock a Buy Now?
A 57% risk reduction for heart attacks and strokes sounds like an amazing result. 
Via The Motley Fool
Inflation's Stubborn Grip: PCE Index and Fed's Dilemma
The specter of persistent inflation continues to loom large over the U.S. economy, keeping both consumers and policymakers on edge. Despite the Federal Reserve's aggressive campaign of interest rate... 
Via MarketMinute
Topics Bonds Economy Supply Chain
EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death
Novo Nordisk's Wegovy cut cardiovascular risks significantly versus tirzepatide in a real-world study, showing fewer heart attacks, strokes, and deaths. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS